SCOTTSDALE, Ariz. — September 22, 2026
Applied Biologics announced Last Patient, Last Visit (LPLV) in the 222-patient CAMPX multicenter randomized controlled clinical trial evaluating XWRAP® plus standard of care versus standard of care alone in patients with chronic diabetic foot ulcers. The milestone completes all scheduled patient participation and moves the study into final data reconciliation, clinical quality activities, database lock and statistical analysis. CAMPX was designed to evaluate complete wound closure following a 12-week treatment period, with wound closure assessed using rigorous criteria and independent blinded adjudication.
CAMPX Advances Toward Final Database Lock
CAMPX enrolled patients with Wagner grade 1 and Wagner grade 2 diabetic foot ulcers and was designed to generate prospective randomized evidence for XWRAP in chronic wound management. The study’s primary assessment focuses on complete wound closure during the 12-week treatment period. Applied Biologics said previously reported interim analyses showed statistically significant differences in complete wound closure favoring XWRAP plus standard of care, while emphasizing that these findings remain interim and should not be considered final results. The company will conduct its final analysis after completion of data reconciliation and database lock.
XWRAP Clinical Evidence Program Expands
The completion of patient follow-up represents a major milestone in Applied Biologics’ clinical evidence strategy for XWRAP, which includes randomized controlled trials, translational research, real-world outcomes studies, health economic research and scientific publication. The company said updated CAMPX clinical results have been submitted for scientific presentation and publication, while independent clinical quality review and final data preparation continue. XWRAP is an advanced wound care technology used as a wound cover for chronic wounds and as a tissue-plane barrier during surgical procedures.
Advertisement
Applied Biologics Advances BIOxHEAL Phase 3 Program
Applied Biologics is simultaneously advancing BIOxHEAL™ into Phase 3 clinical development for chronic diabetic foot ulcers, with patient enrollment now underway. The company is also conducting preclinical gene therapy research focused on potential disease-modifying treatments for osteoarthritis and other degenerative diseases. Following CAMPX LPLV, the next major milestones include database lock, completion of final statistical analyses and reporting of final study results, which will provide the definitive assessment of the XWRAP treatment strategy in the trial.
Source :Applied Biologics press release
